EladSharonMD

PubMed

• Randomized Phase II Study to Assess the Role of Single-Agent Nivolumab to Maintain Remission in Acute Myeloid Leukemia.
  Athalia Rachel Pyzer, Laura W Dillon, Elad Sharon, Theodore G Karrison, Yuanyuan Zha
  Blood Advances. 2025-02-10
• The use of large language models to enhance cancer clinical trial educational materials.
  Mingye Gao, Aman Varshney, Shan Chen, Vikram Goddla, Jack Gallifant
  JNCI Cancer Spectrum. 2025-02-08
• 2 citations
  Cancer Immunotherapy Trials Network 12: Pembrolizumab in HIV-Associated Kaposi Sarcoma.
  Kathryn Lurain, Ramya Ramaswami, Irene Ekwede, Vanessa Eulo, Gaurav Goyal
  Journal of Clinical Oncology. 2025-02-01

Journal Articles

• Pembrolizumab in Mycosis Fungoides and Sézary Syndrome: Updated Results of the CITN Multicenter Phase 2 Study  
  Michael S Khodadoust, Pierluigi Porcu, Francine Foss, Andrei R Shustov, Satish Shanbhag, Lubomir Sokol, Steven M Horwitz, Elad Sharon, European Journal of Cancer
• Immuno-Oncology Trial Endpoints: Capturing Clinically Meaningful Activity  
  Elad Sharon, Patrick M Forde, Valsamo Anagnostou, Hao Wang, Franco Verde, Mark Yarchoan, Clinical Cancer Research
• From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely  
  Arta M Monjazeb, Elad Sharon, Clinical Cancer Research

Abstracts/Posters

• Safety and Efficacy of Brentuximab Vedotin in Combination with AVD in Stage II-IV HIV-Associated Classical Hodgkin Lymphoma: Results of the Phase 2 Study, AMC 085
  Elad Sharon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019